Biosimilars Market, By Drug Class, By Indication, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

Description

REPORT HIGHLIGHT

Biosimilars Market size was valued at USD 30,409.32 Million in 2024, expanding at a CAGR of 16.29% from 2024 to 2032.

Biosimilars are biologic medical products highly similar to an already approved reference product, known as the originator, in terms of structure, function, and clinical efficacy. They are developed after the patent expiration of the reference product and undergo rigorous testing to demonstrate similarity in terms of quality, safety, and effectiveness. Unlike generic drugs, which are identical to their branded counterparts, biosimilars may have slight variations due to the complexity of biologic production processes. They offer more affordable treatment options and increase access to critical therapies, particularly for diseases such as cancer, rheumatoid arthritis, and diabetes.

Biosimilars Market- Market Dynamics

Cost-Effectiveness of Biosimilars

The primary driver of the biosimilars market is the increasing demand for cost-effective biologic therapies. As the cost of originator biologics rises, healthcare systems and patients are seeking more affordable alternatives. Biosimilars provide a cost-efficient option without compromising on safety or efficacy, which helps alleviate the financial burden on healthcare systems and patients. This demand for lower-cost therapies, coupled with the expiration of patents for major biologic drugs, creates significant growth opportunities for biosimilars, especially in markets with high healthcare spending pressures.

Biosimilars Market- Key Insights

According to our research analyst, the global Biosimilars Market is expected to develop at a CAGR of approximately 16.29% between 2024-2032.

Segmented by Drug Class in 2023, the Monoclonal Antibodies category dominated the market.

Based on Indication, the Oncology segment generated the most income in 2023.

On the basis of region, in 2023, North America was the region with the highest revenue.

Biosimilars Market- Segmentation Analysis:

The global Biosimilars Market is divided into three categories: Drug Class, Indication and Region.

The biosimilars market is categorized into several drug classes, each serving distinct therapeutic needs. These include Monoclonal Antibodies, used for cancer, autoimmune diseases, and organ transplants; Granulocyte Colony-Stimulating Factor, aiding in neutropenia treatment; Insulin, critical for diabetes management; Erythropoietin, used in anemia treatment; Recombinant Human Growth Hormone, for growth hormone deficiency; Etanercept, treating autoimmune diseases; Follitropin, for fertility treatments; Teriparatide, in osteoporosis therapy; Interferons, for viral infections and certain cancers; Anticoagulants, in blood clot prevention; and Other Drug Classes, covering various biologic therapies. Among these, Monoclonal Antibodies dominate the biosimilars market. They are widely used in treating cancer, rheumatoid arthritis, and inflammatory conditions, representing a significant portion of the market due to their high demand and clinical impact, as well as the expiration of patents on blockbuster biologics in this class.

The biosimilars market is segmented based on various indications, each catering to different therapeutic needs. These include Oncology, where biosimilars are used to treat cancers like breast, colorectal, and lung cancer; Inflammatory & Autoimmune Diseases, targeting conditions such as rheumatoid arthritis and psoriasis; Chronic Diseases, including diabetes and cardiovascular diseases; Blood Disorders, such as anemia and neutropenia; Growth Hormone Deficiency, for children and adults with growth issues; Infectious Diseases, where biosimilars are used in the treatment of conditions like Hepatitis C and HIV; and Other Indications, covering a wide range of therapeutic areas. Among these, Oncology is the dominant indication for biosimilars. The high prevalence of cancer, combined with the need for cost-effective treatment options, drives the demand for biosimilar monoclonal antibodies. Additionally, several blockbuster biologics in oncology have lost patent protection, further boosting the adoption of biosimilars in cancer treatment.

Biosimilars Market- Geographical Insights

Geographically, the Biosimilars Market is distributed throughout North America, Asia Pacific, Latin America, Europe, the Middle East, and Africa. These regions are further divided based on the nations bringing in business.

North America holds a dominant share in the global biosimilars market, driven primarily by the United States. The U.S. is one of the largest markets for biosimilars, owing to the high demand for cost-effective biologic treatments, the presence of a robust healthcare system, and strong regulatory support from the FDA. The expiration of patents for numerous blockbuster biologics, especially in oncology and autoimmune diseases, further fuels biosimilar adoption. Additionally, the growing number of biosimilar approvals, increasing healthcare costs, and an aging population are major factors contributing to market growth. The implementation of policies aimed at reducing drug spending and the push for biosimilars from both the government and private insurers have strengthened the market in the region.

Europe is another major player in the biosimilars market, with countries such as Germany, the UK, and France leading the charge. The European Medicines Agency (EMA) has been a key regulatory body in supporting the development and approval of biosimilars, providing a more favorable environment for these products. European nations have actively embraced biosimilars to reduce healthcare costs, especially in the treatment of chronic diseases like cancer and rheumatoid arthritis. The cost-effectiveness of biosimilars, along with their proven clinical efficacy, has resulted in high adoption rates across the continent. Strong governmental support and favorable pricing regulations have allowed biosimilars to gain significant market penetration, establishing Europe as a dominant force in the global market.

Biosimilars Market- Competitive Landscape:

The biosimilars market is dominated by major pharmaceutical companies such as Novartis AG, Pfizer Inc., Amgen Inc., and F. Hoffmann-La Roche Ltd., which have extensive portfolios and strong R&D capabilities. These companies focus on expanding their biosimilar offerings, particularly in oncology, autoimmune diseases, and chronic conditions, to capture a significant share of the growing market. In addition to these veteran players, Dr. Reddy's Laboratories, Teva Pharmaceutical Industries, and Celltrion Healthcare are making substantial strides with innovative biosimilars, gaining regulatory approvals in key markets like the U.S. and Europe. New entrants like Biocon and Kashiv Biosciences are leveraging cost-effective strategies and regional market expertise to challenge established players. This competitive environment fosters continuous innovation and price competition, ultimately benefiting patients by improving access to biologic treatments.

Recent Developments:

In June 2024, the U.S. FDA released new draft guidance allowing biosimilar manufacturers to demonstrate interchangeability through existing datasets, potentially reducing the need for additional switching studies. This move aims to streamline the approval process and enhance market competition.

In May 2024, Biocon Biologics' aflibercept biosimilar, branded as YESAFILI, received U.S. FDA approval. This marks Biocon's entry into the U.S. ophthalmology market, offering a cost-effective alternative for retinal disorder treatments.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL BIOSIMILARS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Novartis AG
Pfizer Inc.
Amgen Inc.
Dr. Reddy's Laboratories Ltd.
Eli Lilly And Company
Teva Pharmaceutical Industries
Fresenius Kabi AG
Stada Arzneimittel AG
Boehringer Ingelheim International Gmbh
F. Hoffmann-La Roche Ltd
Celltrion Healthcare Co., Ltd.
Samsung Biologics
Coherus Biosciences
Biocon
Amega Biotech
Apotex Inc.
Biocad
Mabxience
Probiomed
Fujifilm Kyowa Kirin Biologics Co., Ltd.
Intas Pharmaceuticals Ltd.
Reliance Life Sciences
Kashiv Biosciences, LLC
Usv Private Limited
Amneal Pharmaceuticals, Inc.
Others

GLOBAL BIOSIMILARS MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

Monoclonal Antibodies
Infliximab
Rituximab
Trastuzumab
Adalimumab
Other Monoclonal Antibodies
Granulocyte Colony-Stimulating Factor
Insulin
Erythropoietin
Recombinant Human Growth Hormone
Etanercept
Follitropin
Teriparatide
Interferons
Anticoagulants
Other Drug Classes

GLOBAL BIOSIMILARS MARKET, BY INDICATION - MARKET ANALYSIS, 2019 - 2032

Oncology
Inflammatory & Autoimmune Diseases
Chronic Diseases
Blood Disorders
Growth Hormone Deficiency
Infectious Diseases
Other Indications

GLOBAL BIOSIMILARS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
The U.S.
Canada
Europe
Germany
France
Italy
Spain
United Kingdom
Russia
Netherlands
Sweden
Poland
Rest of Europe
Asia Pacific
India
China
South Korea
Japan
Australia
Thailand
Indonesia
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
United Arab Emirates
Israel
Turkey
Algeria
Egypt
Rest of MEA

Product Code: ANV5199

1. Biosimilars Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Biosimilars Market Snippet by Drug Class
- 2.1.2. Biosimilars Market Snippet by Indication
- 2.1.3. Biosimilars Market Snippet by Country
- 2.1.4. Biosimilars Market Snippet by Region
2.2. Competitive Insights

3. Biosimilars Key Market Trends

3.1. Biosimilars Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Biosimilars Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Biosimilars Market Opportunities
3.4. Biosimilars Market Future Trends

4. Biosimilars Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Biosimilars Market: COVID-19 Impact Analysis

5.1. Pre-COVID-19 Impact Analysis
5.2. Post-COVID-19 Impact Analysis
- 5.2.1. Top Performing Segments
- 5.2.2. Marginal Growth Segments
- 5.2.3. Top Looser Segments
- 5.2.4. Marginal Loss Segments

6. Biosimilars Market Landscape

6.1. Biosimilars Market Share Analysis, 2023
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Biosimilars Market - By Drug Class

7.1. Overview
- 7.1.1. Segment Share Analysis, By Drug Class, 2023 & 2032 (%)
- 7.1.2. Monoclonal Antibodies
  - 7.1.2.1. Infliximab
  - 7.1.2.2. Rituximab
  - 7.1.2.3. Trastuzumab
  - 7.1.2.4. Adalimumab
  - 7.1.2.5. Other Monoclonal Antibodies
- 7.1.3. Granulocyte Colony-Stimulating Factor
- 7.1.4. Insulin
- 7.1.5. Erythropoietin
- 7.1.6. Recombinant Human Growth Hormone
- 7.1.7. Etanercept
- 7.1.8. Follitropin
- 7.1.9. Teriparatide
- 7.1.10. Interferons
- 7.1.11. Anticoagulants
- 7.1.12. Other Drug Classes

8. Biosimilars Market - By Indication

8.1. Overview
- 8.1.1. Segment Share Analysis, By Indication, 2023 & 2032 (%)
- 8.1.2. Oncology
- 8.1.3. Inflammatory & Autoimmune Diseases
- 8.1.4. Chronic Diseases
- 8.1.5. Blood Disorders
- 8.1.6. Growth Hormone Deficiency
- 8.1.7. Infectious Diseases
- 8.1.8. Other Indications

9. Biosimilars Market- By Geography

9.1. Introduction
- 9.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
9.2. North America
- 9.2.1. Overview
- 9.2.2. Biosimilars Key Manufacturers in North America
- 9.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 9.2.4. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 9.2.5. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.2.6. U.S.
  - 9.2.6.1. Overview
  - 9.2.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.2.6.3. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 9.2.6.4. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.2.7. Canada
  - 9.2.7.1. Overview
  - 9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.2.7.3. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 9.2.7.4. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
9.3. Europe
- 9.3.1. Overview
- 9.3.2. Biosimilars Key Manufacturers in Europe
- 9.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 9.3.4. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 9.3.5. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.3.6. Germany
  - 9.3.6.1. Overview
  - 9.3.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.6.3. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 9.3.6.4. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.3.7. France
  - 9.3.7.1. Overview
  - 9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.7.3. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 9.3.7.4. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.3.8. Italy
  - 9.3.8.1. Overview
  - 9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.8.3. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 9.3.8.4. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.3.9. Spain
  - 9.3.9.1. Overview
  - 9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.9.3. United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 9.3.9.4. United Kingdom Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.3.10. United Kingdom
  - 9.3.10.1. Overview
  - 9.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.10.3. United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 9.3.10.4. United Kingdom Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.3.11. Russia
  - 9.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.11.2. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 9.3.11.3. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.3.12. Netherlands
  - 9.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.12.2. Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 9.3.12.3. Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.3.13. Sweden
  - 9.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.13.2. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 9.3.13.3. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.3.14. Poland
  - 9.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.14.2. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 9.3.14.3. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.3.15. Rest of Europe
  - 9.3.15.1. Overview
  - 9.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.15.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 9.3.15.4. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
9.4. Asia Pacific (APAC)
- 9.4.1. Overview
- 9.4.2. Biosimilars Key Manufacturers in Asia Pacific
- 9.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 9.4.4. Asia Pacific Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 9.4.5. Asia Pacific Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.4.6. India
  - 9.4.6.1. Overview
  - 9.4.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.6.3. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 9.4.6.4. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.4.7. China
  - 9.4.7.1. Overview
  - 9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.7.3. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 9.4.7.4. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.4.8. South Korea
  - 9.4.8.1. Overview
  - 9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.8.3. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 9.4.8.4. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.4.9. Japan
  - 9.4.9.1. Overview
  - 9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.9.3. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 9.4.9.4. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.4.10. Australia
  - 9.4.10.1. Overview
  - 9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.10.3. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 9.4.10.4. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.4.11. Thailand
  - 9.4.11.1. Overview
  - 9.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.11.3. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 9.4.11.4. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.4.12. Indonesia
  - 9.4.12.1. Overview
  - 9.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.12.3. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 9.4.12.4. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.4.13. Philippines
  - 9.4.13.1. Overview
  - 9.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.13.3. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 9.4.13.4. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.4.14. Rest of APAC
  - 9.4.14.1. Overview
  - 9.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.14.3. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 9.4.14.4. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
9.5. Latin America
- 9.5.1. Overview
- 9.5.2. Biosimilars Key Manufacturers in Latin America
- 9.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 9.5.4. Latin America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 9.5.5. Latin America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.5.6. Brazil
  - 9.5.6.1. Overview
  - 9.5.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.5.6.3. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 9.5.6.4. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.5.7. Mexico
  - 9.5.7.1. Overview
  - 9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.5.7.3. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 9.5.7.4. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.5.8. Argentina
  - 9.5.8.1. Overview
  - 9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.5.8.3. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 9.5.8.4. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.5.9. Colombia
  - 9.5.9.1. Overview
  - 9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.5.9.3. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 9.5.9.4. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.5.10. Rest of LATAM
  - 9.5.10.1. Overview
  - 9.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.5.10.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 9.5.10.4. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
9.6. Middle East and Africa
- 9.6.1. Overview
- 9.6.2. Biosimilars Key Manufacturers in Middle East and Africa
- 9.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 9.6.4. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 9.6.5. Middle East and Africa Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.6.6. Saudi Arabia
  - 9.6.6.1. Overview
  - 9.6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.6.6.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 9.6.6.4. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.6.7. United Arab Emirates
  - 9.6.7.1. Overview
  - 9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.6.7.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 9.6.7.4. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.6.8. Israel
  - 9.6.8.1. Overview
  - 9.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.6.8.3. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 9.6.8.4. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.6.9. Turkey
  - 9.6.9.1. Overview
  - 9.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.6.9.3. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 9.6.9.4. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.6.10. Algeria
  - 9.6.10.1. Overview
  - 9.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.6.10.3. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 9.6.10.4. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.6.11. Egypt
  - 9.6.11.1. Overview
  - 9.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.6.11.3. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 9.6.11.4. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.6.12. Rest of MEA
  - 9.6.12.1. Overview
  - 9.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.6.12.3. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 9.6.12.4. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)

10. Key Vendor Analysis- Biosimilars Industry

10.1. Competitive Dashboard
10.2. Company Profiles
- 10.2.1. Novartis Ag
- 10.2.2. Pfizer Inc.
- 10.2.3. Amgen Inc.
- 10.2.4. Dr. Reddy's Laboratories Ltd.
- 10.2.5. Eli Lilly And Company
- 10.2.6. Teva Pharmaceutical Industries
- 10.2.7. Fresenius Kabi Ag
- 10.2.8. Stada Arzneimittel Ag
- 10.2.9. Boehringer Ingelheim International Gmbh
- 10.2.10. F. Hoffmann-La Roche Ltd
- 10.2.11. Celltrion Healthcare Co., Ltd.
- 10.2.12. Samsung Biologics
- 10.2.13. Coherus Biosciences
- 10.2.14. Biocon
- 10.2.15. Amega Biotech
- 10.2.16. Apotex Inc.
- 10.2.17. Biocad
- 10.2.18. Mabxience
- 10.2.19. Probiomed
- 10.2.20. Fujifilm Kyowa Kirin Biologics Co., Ltd.
- 10.2.21. Intas Pharmaceuticals Ltd.
- 10.2.22. Reliance Life Sciences
- 10.2.23. Kashiv Biosciences, Llc
- 10.2.24. Usv Private Limited
- 10.2.25. Amneal Pharmaceuticals, Inc.
- 10.2.26. Others

11. 360 Degree Analyst View

12. Appendix

12.1. Research Methodology
12.2. References
12.3. Abbreviations
12.4. Disclaimer
12.5. Contact Us